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SUMMARY
Here a young patient (< 21 years of age) with a history of infective dermatitis is described. The patient was diagnosed with 
myelopathy associated with HTLV-1/tropical spastic paraparesis and treated with interferon beta-1a. The disease was clinically 
established as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and laboratory tests confirmed the presence 
of antibodies to HTLV-1 in the cerebrospinal fluid (CSF). Mumps, cytomegalovirus, Epstein-Barr virus, schistosomiasis, herpes 
virus 1 and 2, rubella, measles, varicella-zoster toxoplasmosis, hepatitis, HIV, and syphilis were excluded by serology. The patient 
was diagnosed with neurogenic bladder and presented with nocturia, urinary urgency, paresthesia of the lower left limb, a marked 
reduction of muscle strength in the lower limbs, and a slight reduction in upper limb strength. During the fourth week of treatment 
with interferon beta-1a, urinary urgency and paresthesia disappeared and clinical motor skills improved.
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INTRODUCTION
The human T-lymphotropic virus (HTLV) is a retrovirus belonging 
to the Retroviridae family. HTLV can infect cells of the human immune 
system and has tropism for T-lymphocytes14,15 (T-cells). Approximately 
10-20 million people worldwide are infected with HTLV-1, which is 
considered a global epidemic. HTLV-1 is associated with a wide spectrum 
of manifestations including tropical spastic paraparesis, a disease 
characterized by the slow and progressive development of myelopathy, 
as well as leukemia/lymphoma in adult T-cells6. HTLV-1 is endemic in 
many regions of the world, more common in adult women, and usually 
insidious, but may be sudden. There is a high prevalence of HTLV-1 
in southern Japan, the Caribbean, Africa, South America, Papua New 
Guinea, the Middle East, Australia, and Southeast Italy11. In Brazil, 
HTLV-1 is found in several states, but is more prevalent in certain regions, 
such as in the Northeast, particularly Maranhão, where the prevalence is 
10 per 1000 blood donors3. 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/
TSP) is a demyelinating disease with inflammatory changes in the 
central nervous system. HTLV-1 is predominantly transmitted via 
blood; however, vertical and sexual transmission is also possible12. 
HAM/TSP is characterized by neurological manifestations, such as 
chronic spastic paraparesis, impaired gait, and weakness in the lower 
limbs. Other symptoms include sphincter signs and symptoms such as 
bladder disorders (urinary urge incontinence and nocturia) and sensory 
symptoms including paresthesia, hyperreflexia of the lower limbs, and 
the presence of the Babinski signal often with clonus (signs of pyramidal 
release). Laboratory diagnosis is made by the identification of HTLV-
1/2 antibodies in the blood and cerebrospinal fluid (CSF). Results are 
confirmed by Western blot or detection of proviral DNA in the blood 
or CSF12. 
In this study, a patient with HAM/TSP treated with interferon beta-1a 
was presented, with a good outcome. 
CASE REPORT
A 21-year-old widowed female patient, with a history of infective 
dermatitis in childhood reported, decreased muscle strength in the upper 
and lower limbs, particularly on the right side. The patient was seen 
as a referral to the rehabilitation department. She was diagnosed with 
HTLV-1-associated myelopathy/tropical spastic paraparesis, confirmed 
by positive levels of HTLV in serum (ELISA: 3.15, Cut-Off: 0.18) and the 
CSF (ELISA: 2.57, Cut-Off: 0.18). Additionally, anti-HTLV confirmation 
was made using Western blot analyses.
The referral hospital also identified antibodies in the CSF and 
excluded mumps, cytomegalovirus, Epstein-Barr virus, schistosomiasis, 
herpes virus 1 and 2, rubella, measles, toxoplasmosis, and varicella-zoster 
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virus. Serology for hepatitis, syphilis and HIV were also negative. Protein 
electrophoresis showed albumin values of 15.6 mg/dL (normal range: 
5.6-45.6 mg/dL), beta-globulin values of 5.7 mg/dL (normal range: 
0.8-10.8 mg/dL), and gamma-globulin values of 7.2 mg/dL (normal 
range: 0.3-7.2 mg/dL). The complete blood count (CBC) was 3.09 
million red blood cells (RBCs)/mm3, 9.4 g/dL hemoglobin, hematocrit 
29%, lymphocytes 41%, erythrocyte sedimentation rate (ESR) of 40 mm 
in the first hour, and 192,000 platelets.
A differential diagnosis for demyelinating disease and lupus was 
performed. Lupus and demyelinating disease were ruled out by clinical 
presentation and laboratory tests for lupus (anticoagulant, anticardiolipin 
IgG and IgM, and anti-DNA antibodies, all negatives). The serology of 
the patient’s mother could not be assessed, because she refused testing. 
The patient’s husband was also not tested, because he died before the 
onset of her clinical manifestations. However, the patient has a daughter 
(aged two years) who was seropositive for HTLV-1. 
One year prior to diagnosis of HTLV-1, the patient was diagnosed 
with neurogenic bladder, with clinical nocturia (~four times per night), 
urinary urgency, severe loss of muscle strength in the lower limbs, 
positive Babinski reflex and paresthesia in the left leg. The patient had 
also started walking with support on the right side. The patient could 
walk 10 m in 12 s.
Interferon beta-1a treatment (3,000,000 IU) was started three times a 
week for 10 weeks. Clinical evaluations were performed after four weeks 
of therapy. Improvement was first observed in sensory manifestations 
followed by motor evaluation. The patient showed improvements in 
muscle strength and nocturia (reduced to once per night) with the 
disappearance of urinary urgency and paresthesia. The patient’s gait 
became more agile and quick, and she could walk 10 m in 10 s. Two 
years after completing treatment, the patient still reports improved clinical 
sensory and motor skills.
DISCUSSION
HTLV-1/2 infection is endemic in Brazil4 where 5% of people are 
seropositive. There is a high incidence in Maranhão, where 10 per 1000 
blood donors are seropositive3. HTLV-1/2 is more frequent among 
women10 in the fourth and fifth decade of life5, contrary to the age of the 
patient in this study and the data provided by CARVALHO et al. (2009)2. 
Several promising therapies have been considered and evaluated for 
HAM/TSP, although none have been approved for use in patients yet. 
The treatment of HTLV-1-associated myelopathy/tropical spastic 
paraparesis can be divided into specific and symptomatic cases. Specific 
immunosuppressive drugs (corticosteroids) and/or immunomodulators 
(interferon alpha and beta-1) are used for treatment. These drugs work 
to inhibit T-lymphocyte activation, which modulates leukocyte migration 
and minimizes the production of inflammatory cytokines. There are drugs 
for symptomatic treatment that can control pain, neurogenic bladder, 
constipation, and spasticity1. 
Studies using interferon alpha to treat patients with HAM/TSP have 
shown better clinical outcomes and reduced proviral loads8,13,16. 
Interferon beta-1a has been used to treat relapsing-remitting multiple 
sclerosis and has been shown to be beneficial in several trials7,10. In HAM/
TSP, only two studies evaluated interferon beta-1a treatment. One study 
used a dose of 60 mcg twice per week, which reduced tax-CD8+ cells, 
but did not reduce the proviral DNA load9. The other study used a lower 
dose of 30 mcg every 15 days and noted good outcomes4. 
In this study, it was chosen to treat with interferon beta-1a instead 
of interferon alpha, because the latter has a daily dosage schedule rather 
than the simple weekly interferon beta-1a dosage.
Treatment with interferon beta-1a (3,000,000 IU) three times a 
week for 10 weeks improved the urinary and motor symptoms of the 
patient. Although interferon beta-1a may not be the standard treatment 
for HTLV-1-associated myelopathy/tropical spastic paraparesis, in this 
case it proved to be very promising. This underscores the need for more 
clinical studies using interferon beta-1a.
RESUMO
Tratamento com interferon beta-1a em mielopatia associada ao 
HTLV-1/paraparesia espástica tropical: relato de caso
Descreve-se caso de mielopatia associada ao HTLV-1/paraparesia 
espástica tropical tratada com interferon beta-1a em paciente jovem de 
21 anos e com história de dermatite infecciosa na infância. Foi estabelecida 
clinicamente paraparesia espástica tropical (HAM/TSP), confirmada 
laboratorialmente pela presença de anticorpos para HTLV-1 no LCR e 
excluídas caxumba, citomegalovirus, Epstein-Barr, esquistossomose, 
herpes virus 1 e 2, rubéola, sarampo, toxoplasmose varicela-zoster, hepatite, 
HIV e sífilis por sorologias. Foi diagnosticada bexiga neurogênica, com 
quadro clínico de nictúria, urgência urinária, parestesia no membro inferior 
esquerdo e discreta redução de força muscular nos membros superiores, 
mais acentuada nos membros inferiores. Na 4ª semana de tratamento 
com interferon beta-1a houve desaparecimento da urgência urinária e da 
parestesia e melhora da clínica motora.
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